Metastases Spinal Tumor Market Research Report - Global forecast till 2023

Description:

Metastases spinal tumor market information: by type (extradural, and others), diagnosis (laboratory tests, imaging tests, biopsy, and others), by treatment (non-operative treatment, surgical treatment, and others), by end user- global forecast till 2023

Market Synopsis of Global Metastases Spinal Tumor Market

Market Scenario

Metastases spinal tumor is one of the most common problems in oncology. Approximately 5%-10% of the cancer patients face spinal metastases disease. Most of the metastatic spinal tumors are developed outside the dura (extradural). Around 70% of the spine tumors occur in the thoracic region, while 20% in the lumbar, and 10% in the neck region. Some of the common symptoms of metastases spinal tumor are back pain, tingling or numbness, and weakness.

Early diagnosis can provide better treatment management of this disorder. Major diagnostic solution provider companies are engaged in developing and launching new medical imaging devices. Introduction and rapid adoption of advanced diagnostic devices are driving the market growth. Increasing research, clinical trials, and new solution development in the field of oncology drive the market. Additionally, growing demand for diagnostic devices and treatment from emerging markets of Asia and Latin America add fuel to the growth of the market.

The global metastases spinal tumor market is expected to grow at the CAGR of ~3.2% during the forecast period and is estimated to reach USD 1547.8 million by 2023.

Sources: National Center for Biotechnology Information (NCBI), Cancer Australia, the American Society of Neuroradiology, Directorate of Industries, annual report, white paper, company presentation

Intended Audience

- Metastases Spinal Tumor Diagnostic and Treatment Supplies Companies
- Metastases Spinal Tumor Diagnostic and Treatment Supplies Providers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Segments
The global metastases spinal tumor market is segmented on the basis of type, which comprise extradural, metastatic spinal tumors of the bone, and others.

On the basis of diagnosis, this market is segmented into laboratory tests, imaging tests, biopsy, and others. Imaging tests includes X-Ray, Computed Tomography (CT scan), Magnetic Resonance Imaging (MRI scan), Angiography, F-18 fluorodeoxyglucose positron emission tomography, and others. Biopsy is sub-segmented into percutaneous needle biopsy, open incisional and excisional biopsy, and others.

On the basis of treatments, the market is segmented into non-operative treatment, surgical treatment, and others. Non operative treatment is sub-segmented into medications, radiation therapy, ablation, chemotherapy, and others. Medications includes anti-inflammatory drugs, narcotics (opioids), corticosteroids, rank inhibitors and bisphosphonates, and others. Ablation is further sub-segmented into radiofrequency ablation, cryoablation, and others. Surgical treatment is further sub-segmented into minimally invasive surgery, open surgery, and others. Minimally invasive surgery is sub-segmented into vertebral fracture treatments, transarterial chemoembolization, and others. Vertebral fracture treatments is further sub-segmented into vertebroplasty, kyphoplasty (vertebral augmentation), and others. Open surgery includes spinal stabilization surgery, spinal decompression surgery, and others.

On the basis of end user, it is segmented into hospitals & clinics, ambulatory surgery centers, academic institutes, research centers, and others.

**Research Methodology**

Sources: National Center for Biotechnology Information (NCBI), Cancer Australia, the American Society of Neuroradiology, Directorate of Industries, annual report, white paper, company presentation

**Regional Analysis of the Global Metastases Spinal Tumor Market**

The Americas dominate the global metastases spinal tumor market. An spinal tumor is a severe medical problem in Americas. North American countries such as the US and Canada dominate the market, while, Latin America region is also growing significantly. Due to highly advance medical facilities, focus on research and clinical trials, and upcoming healthcare bill, the US is expected to remain top revenue generating country in the global metastases spinal tumor treatment. Increasing number of patients with metastases spinal tumor is one of the major drivers for the Latin American market.

Europe is the second largest market for metastases spinal tumor treatment. This region is mainly divided into Eastern Europe and Western Europe. The West European countries dominate this market while East European countries also show significant growth. Increasing prevalence of spinal tumor is primarily driving the market growth. Furthermore, some other factors such as availability of advanced healthcare facilities and high expenditure on the health care are driving the growth of the market.

Asia Pacific region is one of the high potential markets in the healthcare sector. This region is showing exceptional growth in almost every product and services mainly related to medical field owing to rising middle-class population and their spending on healthcare and related services. Additionally, increasing awareness about the disease drives the growth of the market. The Governments of different countries are focusing on improvement of public health by providing the subsidy for affordable healthcare as well as running awareness campaign, which, in turn, leads the growth of the market. Some other factors such as increasing cases of metastases spinal tumor, improving healthcare infrastructure, and availability of affordable healthcare facilities are also boosting the market growth. Owing to availability of the cost-effective healthcare facilities, patients from various high-income nations are flying to get affordable treatments, which, in turn, boost the medical tourism in this region.

Lack of awareness about the disorder and limited availability of required healthcare facilities are major restraints for the Middle East & Africa metastases spinal tumor market.
Key Players in the Global Metastases spinal tumor Market
Some of the key players in this market: F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (US), Novartis AG (Switzerland), Abbott (US), Beckman Coulter Inc. (US), Debiopharm Group (Switzerland), AbbVie Inc. (US), Bayer AG (Germany), and others.
7.3.3 Others
7.4 Others

8. Global Metastases spinal tumor Market by Treatment
8.1 Non operative treatment
8.1.1 Medications
8.1.1.1 Anti-inflammatory drugs
8.1.1.2 Narcotics (opioids), Corticosteroids
8.1.1.3 RANKL inhibitors and bisphosphonates
8.1.1.4 Others
8.1.2 Radiation Therapy
8.1.3 Ablation
8.1.3.1 Radiofrequency ablation
8.1.3.2 Cryoablation
8.1.3.3 Others
8.1.4 Chemotherapy
8.1.5 Others
8.2 Surgical treatment
8.2.1 Minimally Invasive Surgery
8.2.1.1 Vertebral Fracture Treatments
8.2.1.1.1 Vertebroplasty
8.2.1.1.2 Kyphoplasty (Vertebral Augmentation)
8.2.1.1.3 Others
8.2.1.2 Transarterial Chemoembolization
8.2.1.3 Others
8.2.2 Open Surgery
8.2.2.1 Spinal Stabilization Surgery
8.2.2.2 Spinal Decompression Surgery
8.2.2.3 Others
8.2.3 Others
8.3 Others

9. Global Metastases spinal tumor Market by End User
9.1 Hospital and clinics
9.2 Ambulatory surgery centers
9.3 Academic institutes
9.4 Research centers
9.5 Others

10. Global Metastases spinal tumor Market by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 The US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Rest of Asia
10.5 Pacific
10.6 Middle East & Africa
10.6.1 UAE
10.6.2 Saudi Arabia
10.6.3 Egypt
10.6.4 Rest of the Middle East & Africa

11. Competitive Landscape
12. Company Profile
13. Conclusion
13.1 Key findings
13.1.1 From CEO’s viewpoint
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Metastases Spinal Tumor Market

14. Appendix